Catestatin

Research-Grade

Catestatin (human chromogranin A352-372) is a 21-amino-acid bioactive peptide generated by proteolytic cleavage of chromogranin A (CgA), a 439-residue acidic glycoprotein stored in and co-released with catecholamines from secretory granules of adrenal chromaffin cells, sympathetic neurons, and other neuroendocrine tissues. Discovered by Sushil Mahata and Daniel O'Connor at the University of California San Diego in 1997, catestatin was identified through its potent ability to inhibit nicotinic acetylcholine receptor (nAChR)-stimulated catecholamine secretion from chromaffin cells — functioning as a physiological brake on the sympathoadrenal system. This autocrine/paracrine negative-feedback mechanism positions catestatin as a critical modulator of sympathetic tone and cardiovascular homeostasis. The cardiovascular effects of catestatin are extensive and well-replicated in preclinical models. It produces vasodilation through histamine release from mast cells and through direct endothelium-dependent nitric oxide production. In rodent models of hypertension, catestatin administration reduces blood pressure, attenuates cardiac hypertrophy, and decreases myocardial fibrosis. Catestatin-knockout mice (CgA-knockout with selective catestatin deficiency) develop hypertension, increased adiposity, insulin resistance, and hepatic steatosis — phenotypes that are rescued by exogenous catestatin replacement. Human genetic studies have identified CgA variants (particularly Gly364Ser and Pro370Leu) that alter catestatin processing and are associated with increased risk of essential hypertension, establishing a direct genetic link between catestatin deficiency and human cardiovascular disease. Circulating catestatin levels are reduced in patients with essential hypertension and in the early stages of heart failure, though levels may paradoxically rise in advanced heart failure as a compensatory response. Beyond the cardiovascular system, catestatin displays broad antimicrobial activity against both Gram-positive and Gram-negative bacteria, fungi, and yeast at micromolar concentrations, functioning as an innate immune effector peptide. It penetrates bacterial membranes through its amphipathic helical structure, similar to classical antimicrobial peptides like LL-37. Catestatin also exerts metabolic effects — it inhibits hepatic glucose output, promotes fatty acid oxidation, suppresses adipose tissue inflammation, and enhances insulin sensitivity in animal models of metabolic syndrome. In the gastrointestinal tract, it modulates gut motility, epithelial barrier function, and intestinal inflammation, with preclinical evidence of protective effects in experimental colitis models. Clinically, catestatin remains in the biomarker and preclinical therapeutic research phase. No catestatin-based therapeutic has entered formal clinical trials, though it has been extensively studied as a circulating biomarker for sympathetic activity, hypertension risk, heart failure prognosis, and metabolic syndrome. The peptide's pleiotropic protective profile — spanning cardiovascular, antimicrobial, metabolic, and anti-inflammatory domains — has generated substantial academic interest, but translation to clinical therapeutics is complicated by its short plasma half-life and the need for stable analogs or delivery systems suitable for chronic administration.